| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PSMD9 |
| Uniprot No | O00233 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-223aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMSDEEARQSGGSSQAGVVTVSDVQELM RRKEEIEAQIKANYDVLESQKGIGMNEPLVDCEGYPRSDVDLYQVRTARH NIICLQNDHKAVMKQVEEALHQLHARDKEKQARDMAEAHKEAMSRKLGQS ESQGPPRAFAKVNSISPGSPASIAGLQVDDEIVEFGSVNTQNFQSLHNIG SVVQHSEGKPLNVTVIRRGEKHQLRLVPTRWAGKGLLGCNIIPLQR |
| 预测分子量 | 27 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PSMD9重组蛋白的3篇参考文献，按文献名称、作者和摘要内容概括列出：
---
1. **文献名称**: *"Recombinant PSMD9 promotes the assembly of 26S proteasome in vitro"*
**作者**: Tanaka K, et al.
**摘要**: 研究通过重组表达PSMD9蛋白，证明其在体外促进26S蛋白酶体组装中的关键作用，揭示了PSMD9与其他亚基的相互作用机制。
---
2. **文献名称**: *"Structural and functional characterization of the human PSMD9 subunit of the 19S regulatory particle"*
**作者**: Smith J, Wang L.
**摘要**: 利用重组PSMD9蛋白进行晶体结构解析，揭示了其与去泛素化酶USP14的结合界面，为靶向蛋白酶体的药物开发提供结构基础。
---
3. **文献名称**: *"PSMD9 overexpression enhances cellular proteasome activity and reduces oxidative stress in mammalian cells"*
**作者**: Chen H, et al.
**摘要**: 通过重组PSMD9在HEK293细胞中的过表达实验，发现其可提升蛋白酶体活性并降低氧化应激损伤，提示其在神经退行性疾病中的潜在治疗价值。
---
注：以上文献信息为示例性内容，实际文献需通过学术数据库(如PubMed、Web of Science)检索确认。
**Background of PSMD9 Recombinant Protein**
PSMD9 (Proteasome 26S Subunit, Non-ATPase 9) is a critical component of the 26S proteasome, a large multiprotein complex responsible for the ubiquitin-proteasome system (UPS), the primary pathway for regulated intracellular protein degradation in eukaryotes. The 26S proteasome consists of a 20S catalytic core and one or two 19S regulatory particles. PSMD9. part of the 19S regulatory subunit, plays a role in substrate recognition, deubiquitination, and unfolding of polyubiquitinated proteins prior to their degradation. This process is essential for maintaining cellular homeostasis, regulating processes like cell cycle progression, stress responses, and apoptosis.
Recombinant PSMD9 protein is produced using genetic engineering techniques, often expressed in systems such as *E. coli*, yeast, or mammalian cells to ensure proper folding and post-translational modifications. The recombinant form enables researchers to study PSMD9’s structure, interactions, and function in vitro or in cellular models. It is typically purified via affinity tags (e.g., His-tag, GST-tag) and validated for activity using assays like co-immunoprecipitation or enzymatic degradation studies.
Research on PSMD9 recombinant protein has provided insights into proteasome assembly, substrate specificity, and its role in diseases. Dysregulation of the UPS is linked to cancers, neurodegenerative disorders (e.g., Alzheimer’s, Parkinson’s), and autoimmune conditions. PSMD9 has been implicated in cancer progression, where its overexpression may correlate with poor prognosis, suggesting therapeutic potential as a drug target. Additionally, studying recombinant PSMD9 aids in developing proteasome inhibitors (e.g., bortezomib) and understanding resistance mechanisms in therapies.
Overall, PSMD9 recombinant protein serves as a vital tool for dissecting proteasome biology and exploring therapeutic strategies targeting protein degradation pathways.
×
